For immediate release |
2 August 2017 |
|
|
RNS Reach
Evgen Pharma plc
("Evgen Pharma" or "the Company")
SFX-01 data published in Peer Reviewed Journal
Evgen Pharma's SFX-01 protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis
Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the publication in a peer reviewed scientific journal of its lead product, SFX-01 and its protective effects against osteoarthritis.
The paper, "Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis", has been published in the journal Bone and describes the work undertaken by researchers to see how SFX-01 modifies gait, bone architecture and slows or reverses articular cartilage destruction in a spontaneous osteoarthritis model in mice.
The paper can be viewed at: http://www.thebonejournal.com/article/S8756-3282(17)30263-6/fulltext?cc=y= (Behzad Javaheri et al; Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis, Bone, 2017).
This follows the news in the AGM Statement announced on 26 July 2017, that Evgen, together with the RVC, University of London, has secured grant funding to continue its collaboration to build on this, now published, preclinical data demonstrating the potential of SFX-01 as a treatment for osteoarthritis.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com |
c/o +44 (0) 20 7466 5000 |
|
|
Buchanan Mark Court, Sophie Cowles, Stephanie Watson |
+44 (0) 20 7466 5000 |
|
|
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes, Rob Rees (Corporate Broking) |
+44 (0) 20 3861 6625 |
|
|
|
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
